VivoSeq
Oncology

Metastatic Breast Cancer

23

Pipeline Programs↗

13

Active Trials↗

14

Companies Involved↗

Metastatic Breast Cancer is an emerging landscape with 23 programs across 14 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Sermonix Pharmaceuticals Inc., Eli Lilly. 6 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

67/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2S

Sermonix Pharmaceuticals Inc.

2 programs

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Pfizer logo

Pfizer

2 programs

Phase 3Roche logo

Roche

5 programs

Phase 3T

TerSera Therapeutics LLC

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

81%

Small molecule

21 of 26 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody312%Antibody–drug conjugate28%

Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 93% of 28 pipeline programs.

Analysis

Trial Status

16

clinical trials

Recruiting9 · 56%
Active, not recruiting2 · 13%
Completed2 · 13%
Not yet recruiting2 · 13%
Terminated1 · 6%

Clinical Trials

Trial Activity

16 trials

Fast-Her: Fasting Effects on Breast Cancer Treatment
Recruiting·UUniversity of Minnesota·Preclinical·NCT07624617·15 enrolled
Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Preclinical·NCT06324357·768 enrolled
A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer
Recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT06110793·56 enrolled
Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer
Recruiting·UUniversity of California, San Francisco·N/A·NCT05964504·12 enrolled
Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail
Recruiting·WWake Forest University Health Sciences·Phase 2·NCT02422641·16 enrolled
Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer, With and Without Prior Therapies inMetastatic Setting, and During First-line Aromatase InhibitorPlus CDK4/6 Inhibitor Therapy, in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT06417801·170 enrolled
Comparing Oral Drug Dosing Strategies in Older Patients With Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Recruiting·AAmerican Society of Clinical Oncology·Phase 3·NCT06377852·500 enrolled
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Recruiting·Roche logoRoche·Phase 3·NCT05894239·230 enrolled
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Recruiting·LLeonaBio·Phase 3·NCT05696626·600 enrolled
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastic Breast Cancer After Progression on Previous Endocrine Therapy (LITESPARK-029)
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT06428396·120 enrolled
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study
Active, not recruiting·Novartis logoNovartis·Approved·NCT05161195·134 enrolled
Image-Guided Pulsed Electric Field (PEF) Ablation of Soft Tissue Lesions in Metastatic Breast Cancer: A Pilot Study
Not yet recruiting·UUniversity of California, San Francisco·Preclinical·NCT07487844·20 enrolled
CRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer
Not yet recruiting·HHospices Civils de Lyon·Preclinical·NCT07676344·42 enrolled
Effects of a Multimodal Community-based Intervention Combining Physical Exercise and Health Education Workshops on Quality of Life in Women With Metastatic Breast Cancer: a Longitudinal Pre-post Study.
Completed·UUniversity of Valencia·Preclinical·NCT07693985·37 enrolled
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies Assessed in a Real-World Non-Interventional Study (EUCHARIS)
Completed·Pfizer logoPfizer·N/A·NCT05043506·1,939 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)